Indacaterol ; Defination, Mechanism, Indications, Contra indications,Dosage, Side effects, Drug Interaction ,Pregnancy Catagory

0
79
rx photo gallary

Indacaterol (INN) is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler

Mechanism of action

Indacaterol works by stimulating adrenergic beta-2 receptors in the smooth muscle of the airways. This causes relaxation of the muscle, thereby increasing the diameter of the airways, which become constricted in asthma and COPD. It is also long acting due to its high affinity to the lipid raft domains in the airway membrane so it slowly dissociates from the receptors. Indacaterol also has a high intrinsic efficacy so it is also very rapid acting – onset of action occurs within 5 minutes.

The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3-receptors. This selectivity profile is similar to formoterol. The clinical significance of these findings is unknown.

Indications 

Contra Indications

Allergies to

  • Beta-Adrenergic Agents

Dosage

Strengths: 75 mcg

Chronic Obstructive Pulmonary Disease – Maintenance

1 inhalation (75 mcg) orally once a day

Side Effects

The most common

More common

Rare

Drug Interactions

Indacaterol may interact with following drugs,suppliment & may change the efficacy of drugs

Pregnancy Catagory

FDA Pregnancy Category C

Pregnancy

Indacaterol falls into category C. There are no well-done studies that have been done in humans with indacaterol. But in animal studies, pregnant animals were given this medication, and the babies did not show any medical issues related to this medication.

Lactation

It is not known if indacaterol crosses into human milk. Because many medications can cross into human milk and because of the possibility for serious adverse reactions in nursing infants with use of this medication, a choice should be made whether to stop nursing or stop the use of this medication.https://www.rxharun.com/advertising-warning- logo

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here